FDA
-
-
-
-
-
-
-
InflaRx advances izicopan development for kidney diseases
-
-
-
-
-
-
-
InflaRx Highlights Clinical Activity of Vilobelimab in Pyoderma Gangrenosum in Late-Breaker Oral Presentation at 2026 American Academy of Dermatology Annual Meeting
-
-
-
-
-
-
-
InflaRx sees signals of efficacy in vilobelimab pyoderma gangrenosum trial
-
-
-
-
-
-
-
InflaRx Reports Second Quarter 2025 Financial Results and Provides Business Update
-
-
-
-
-
-
-
InflaRx to Showcase Vilobelimab’s Role in Immuno-Dermatology at the 2025 AAD Annual Meeting
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Inflarx NV (IFRX)
-
-
-
-
-
-
-
InflaRx Hosts R&D Event Highlighting the Promise of INF904
-
335,221 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


